×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KOD – kodiak sciences inc (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KOD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
12:02 pm
kod
Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines [Seeking Alpha]
Low
Report
Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines [Seeking Alpha]
3/27
11:52 am
kod
Kodiak Sciences (KOD) had its price target raised by UBS Group AG from $50.00 to $80.00. They now have a "buy" rating on the stock.
High
Report
Kodiak Sciences (KOD) had its price target raised by UBS Group AG from $50.00 to $80.00. They now have a "buy" rating on the stock.
3/27
08:02 am
kod
Kodiak Sciences (KOD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock, up from $38.00.
Medium
Report
Kodiak Sciences (KOD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $58.00 price target on the stock, up from $38.00.
3/26
11:40 pm
kod
Kodiak Sciences (KOD) CLimbs 75% on Stellar Clinical Results [Yahoo! Finance]
Medium
Report
Kodiak Sciences (KOD) CLimbs 75% on Stellar Clinical Results [Yahoo! Finance]
3/26
06:26 am
kod
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo! Finance]
High
Report
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham [Yahoo! Finance]
3/26
06:00 am
kod
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
High
Report
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
3/14
07:22 pm
kod
Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Weakness And Strong One Year Return [Yahoo! Finance]
Low
Report
Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Weakness And Strong One Year Return [Yahoo! Finance]
3/9
10:19 am
kod
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing [Yahoo! Finance]
Medium
Report
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/27
06:09 pm
kod
Form 4 Kodiak Sciences Inc. For: Mar 25 Filed by: PERLROTH VICTOR
Low
Report
Form 4 Kodiak Sciences Inc. For: Mar 25 Filed by: PERLROTH VICTOR
3/27
06:05 am
kod
Form 8-K Kodiak Sciences Inc. For: Mar 26
Medium
Report
Form 8-K Kodiak Sciences Inc. For: Mar 26
2/17
04:37 pm
kod
Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: Point72 Asset Management, L.P.
Medium
Report
Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: Point72 Asset Management, L.P.
2/17
04:12 pm
kod
Form 5 Kodiak Sciences Inc. For: Dec 31 Filed by: PERLROTH VICTOR
Medium
Report
Form 5 Kodiak Sciences Inc. For: Dec 31 Filed by: PERLROTH VICTOR
2/17
04:09 pm
kod
Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: PERLROTH VICTOR
Medium
Report
Form SCHEDULE 13G/A Kodiak Sciences Inc. Filed by: PERLROTH VICTOR
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
72.5%
12/4 Kodiak Sciences prices $276M equity offering [Seeking Alpha] 49.8%
9/15 Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting 17.2%
11/15 Form EFFECT Kodiak Sciences Inc. 16.6%
12/24 Kodiak Sciences Inc. (NYSE: KOD) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $82.00 price target on the stock. 15.3%
10/10 Form 8-K Kodiak Sciences Inc. For: Oct 04 13.3%
3/18 Form 4 Kodiak Sciences Inc. For: Mar 16 Filed by: BAKER FELIX 12.5%
5/15 Form S-8 Kodiak Sciences Inc. 12.2%
4/29 Form DEFA14A Kodiak Sciences Inc. 9.1%
9/4 Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting 8.3%
12/4 Kodiak Sciences prices $276M equity offering [Seeking Alpha] 49.8%
9/15 Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting 17.2%
11/15 Form EFFECT Kodiak Sciences Inc. 16.6%
12/24 Kodiak Sciences Inc. (NYSE: KOD) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $82.00 price target on the stock. 15.3%
10/10 Form 8-K Kodiak Sciences Inc. For: Oct 04 13.3%
3/18 Form 4 Kodiak Sciences Inc. For: Mar 16 Filed by: BAKER FELIX 12.5%
5/15 Form S-8 Kodiak Sciences Inc. 12.2%
4/29 Form DEFA14A Kodiak Sciences Inc. 9.1%
9/4 Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting 8.3%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.400 ZacksConsensus N/A ActVsEst N/A - N/A
-24.2%
12/4 Form 4 Kodiak Sciences Inc. For: Dec 02 Filed by: Liang Hong -11.0%
11/20 Form 8-K Kodiak Sciences Inc. For: Nov 18 -10.5%
8/14 Q2/2019 6/30/2019 EPS -0.310 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
2/26 Form SC 13D/A Kodiak Sciences Inc. Filed by: BAKER BROS. ADVISORS LP -8.4%
4/6 Form 4 Kodiak Sciences Inc. For: Apr 02 Filed by: Liang Hong -8.2%
12/2 Kodiak Sciences Inc. (NYSE: KOD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $40.00 price target on the stock. -7.9%
4/22 Form 4 Kodiak Sciences Inc. For: Apr 20 Filed by: EHRLICH JASON -6.9%
11/12 Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.330 ActVsEst 0.000 - In-Line -6.1%
11/18 3 Biotech Stock Rockets With More Fuel in the Tank [The Motley Fool] -5.6%
12/4 Form 4 Kodiak Sciences Inc. For: Dec 02 Filed by: Liang Hong -11.0%
11/20 Form 8-K Kodiak Sciences Inc. For: Nov 18 -10.5%
8/14 Q2/2019 6/30/2019 EPS -0.310 ZacksConsensus N/A ActVsEst N/A - N/A -9.9%
2/26 Form SC 13D/A Kodiak Sciences Inc. Filed by: BAKER BROS. ADVISORS LP -8.4%
4/6 Form 4 Kodiak Sciences Inc. For: Apr 02 Filed by: Liang Hong -8.2%
12/2 Kodiak Sciences Inc. (NYSE: KOD) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $40.00 price target on the stock. -7.9%
4/22 Form 4 Kodiak Sciences Inc. For: Apr 20 Filed by: EHRLICH JASON -6.9%
11/12 Q3/2019 9/30/2019 EPS -0.330 ZacksConsensus -0.330 ActVsEst 0.000 - In-Line -6.1%
11/18 3 Biotech Stock Rockets With More Fuel in the Tank [The Motley Fool] -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: